Phase I Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Summary
4/22/2020 Note: This trial is no longer enrolling into Parts B and D.
The purpose of this phase I study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Biomarker testing to determine if patient is eligible for the trial must be completed prior to screening for the trial.
General Information
NCT#: NCT02857270
Study ID: 16419
Trial Phase: Phase I
Trial Sponsor: Eli Lilly
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cetuximab, LY3214996, Abemaciclib, midazolam, Encorafenib